Strides Pharma Gets Tentative Nod From U.S. FDA For Pain Relieving Drug
The U.S. market for Diclofenac Potassium Softgel Capsules of 25 milligrams is approximately $30 million.
Drug firm Strides Pharma Science Ltd. has got tentative approval from U.S. health regulator for Diclofenac Potassium Softgel Capsules, a drug used to relieve pain.
Strides Pharma Global Pte Ltd, Singapore, has received tentative approval for Diclofenac Potassium Softgel Capsules, 25 mg from the United States Food & Drug Administration, Strides Pharma Science said in a regulatory filing.
Strides Pharma Global Pte Ltd is a step-down wholly-owned subsidiary of Strides Pharma Science. The product is a generic version of Zipsor Capsules in the strength of 25 milligrams of Assertio Therapeutics, Inc.
Diclofenac Potassium Softgel capsule is a nonsteroidal anti-Inflammatory drug used to relieve pain and swelling. It is used to treat muscle aches, backaches, dental pain, menstrual cramps, and sports injuries.
Diclofenac Potassium Softgel capsules is part of Strides niche and small volume product portfolio with limited competition in the U.S. market.
According to research firm IQVIA MAT data, the U.S. market for Diclofenac Potassium Softgel capsules, 25 milligrams is approximately $30 million.
Strides can launch the product earliest by September 2022 based on terms of settlement. On receiving full approval, the product will be manufactured at the company's Oral dosage facility in Bengaluru and marketed by Strides Pharma Inc in the U.S. Market.